Diabetes, Vol 46, Issue 4 632-636, Copyright © 1997 by American Diabetes Association

ARTICLES

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

RG Thompson, J Peterson, A Gottlieb and J Mullane
Amylin Pharmaceuticals, Inc., San Diego, California 92121, USA.

The effects of subcutaneous administration of 10, 30, or 100 microg q.i.d. pramlintide, an analog of human amylin, on plasma glucose regulation in patients with IDDM were evaluated in a multicenter trial. The plasma glucose response to a Sustacal test meal was significantly reduced compared with placebo both after 1 week and after 2 weeks of administration of 30 or 100 microg pramlintide. In addition, 24-h mean plasma glucose concentrations were significantly lowered in patients receiving 30 microg of pramlintide for 2 weeks compared with placebo, while the 100-microg pramlintide dose did not reach statistical significance for the 24-h glucose profiles. At 10 microg, pramlintide had no effect on the 24-h glucose profile or on the plasma glucose response to a Sustacal test meal. The reduction in 24-h glucose concentrations and glucose concentrations after the Sustacal test meal observed at the 30-microg pramlintide dose was not accompanied by an increased incidence of hypoglycemic events. The most frequent adverse events were dose-related and involved transient upper gastrointestinal symptoms. A majority (>80%) of the patients who reported these adverse events during week 1 did not report them in week 2. These data indicate that pramlintide effectively reduces plasma glucose concentrations as reflected in both a 24-h glucose profile and a Sustacal test meal while maintaining an acceptable safety profile.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				J. McQueen Pramlintide acetate Am. J. Health Syst. Pharm., November 15, 2005; 62(22): 2363 - 2372. [Abstract] [Full Text] [PDF]

				R. A. Heptulla, L. M. Rodriguez, L. Bomgaars, and M. W. Haymond The Role of Amylin and Glucagon in the Dampening of Glycemic Excursions in Children With Type 1 Diabetes Diabetes, April 1, 2005; 54(4): 1100 - 1107. [Abstract] [Full Text] [PDF]

				A. Ceriello, L. Piconi, L. Quagliaro, Y. Wang, C. A. Schnabel, J. A. Ruggles, M. A. Gloster, D. G. Maggs, and C. Weyer Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes Diabetes Care, March 1, 2005; 28(3): 632 - 637. [Abstract] [Full Text] [PDF]

				O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				C. Weyer, A. Gottlieb, D. D. Kim, K. Lutz, S. Schwartz, M. Gutierrez, Y. Wang, J. A. Ruggles, O. G. Kolterman, and D. G. Maggs Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes: A dose-timing study Diabetes Care, November 1, 2003; 26(11): 3074 - 3079. [Abstract] [Full Text] [PDF]

				E. L Kleppinger and E. M Vivian Pramlintide for the Treatment of Diabetes Mellitus Ann. Pharmacother., July 1, 2003; 37(7): 1082 - 1089. [Abstract] [Full Text] [PDF]

				J. E. Gerich Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia Arch Intern Med, June 9, 2003; 163(11): 1306 - 1316. [Abstract] [Full Text] [PDF]

				C. Levetan, L. L. Want, C. Weyer, S. A. Strobel, J. Crean, Y. Wang, D. G. Maggs, O. G. Kolterman, M. Chandran, S. R. Mudaliar, et al. Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps Diabetes Care, January 1, 2003; 26(1): 1 - 8. [Abstract] [Full Text] [PDF]

				J. B. Buse, C. Weyer, and D. G. Maggs Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy Clin. Diabetes, July 1, 2002; 20(3): 137 - 144. [Abstract] [Full Text] [PDF]

				F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes Diabetes Care, April 1, 2002; 25(4): 724 - 730. [Abstract] [Full Text] [PDF]

				D. F. Kruger, P. M. Gatcomb, and S. K. Owen Clinical Implications of Amylin and Amylin Deficiency The Diabetes Educator, May 1, 1999; 25(3): 389 - 397. [Abstract] [PDF]

				C.M.B. Edwards, M.A. Cohen, and S.R. Bloom Peptides as drugs QJM, January 1, 1999; 92(1): 1 - 4. [Full Text] [PDF]